
Fig. 1: Glucose Infusion Rate (GIR) Lantus U100






Fig. 2: Glucose Infusion Rate (GIR) Lantus U300



HOE901/PKD10086
Arithmetic mean (±SD) for serum insulin concentrations (uIU/mL)
Lantus U100 (Geometric mean of two repeats)
n = 24
Concentration (uIU/mL)
Time (h)
0
5
10
15
20
25
30
35
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30

Fig. 3 (1/2)



HOE901/PKD10086
Arithmetic mean (±SD) for serum insulin concentrations (uIU/mL)
Lantus U300 (Repeat 1)
n = 23
Concentration (uIU/mL)
Time (h)
0
5
10
15
20
25
30
35
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30

Fig. 3 (2/2)




Fig. 4: Blood Glucose (1/2)




Fig. 4: Blood Glucose (2/2)




Fig. 5: Blood Glucose (1/2)









Fig. 5: Blood Glucose (2/2)

Fig. 6:


Concentration – mU/L (values < LOQ are set to zero (0))
Blood glucose – mg/dL
CONCENTRATION - mU/L
BG - mg/dL
TIME - hour

Glucose infusion rate – mg.kg^{-1}.min^{-1}			
			
HOE901-U300 - 0.4 U/kg	**HOE901-U300 - 0.6 U/kg**	**HOE901-U300 - 0.9 U/kg**	**Lantus U100 - 0.4 U/kg**
LOWESS smoothed population averages			

(Fig. 6 continued)

Fig. 7




Lantus and HOE901-U300
GIR-profiles
U100 0.3
U100 0.6
U100 1.2
U100 0.4
U300 0.4
U300 0.6
U300 0.9
GIR - mg.kg-1.min-1
TIME - hour
0
1
2
3
4
5
6
0
6
12
18
24
30
36

Fig. 8


A_Insuline glargine_100 U/mL
diameter: 18,22 µm
diameter: 17,20 µm
diameter: 20,27 µm
500 µm
B_Insuline glargine_300 U/mL
diameter: 64,10 µm
diameter: 67,45 µm
diameter: 49,52 µm
500 µm
C_Insuline glargine_500 U/mL
diameter: 126,17 µm
diameter: 142,51 µm
diameter: 149,65 µm
500 µm
D_Insuline glargine_700 U/mL
diameter: 216,52 µm
diameter: 189,47 µm
diameter: 363,64 µm
500 µm
E_Insuline glargine_1000 U/mL
diameter: 194,96 µm
diameter: 394,98 µm
diameter: 346,71 µm
500 µm



Blood Glucose (mmol/L)
6,0
5,0
4,0
3,0
2,0
1,0
0,0
0
2
4
6
8
10
12
14
16
18
20
22
24
Hours after s.c. Administration
Glargine U-100
Glargine U-300
D080515

Fig. 9